Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma

BACKGROUND: Lung large-cell neuroendocrine carcinoma (L-LCNEC) is a rare and highly aggressive neuroendocrine tumor. There is currently no standard therapeutic regimen, and systemic chemotherapy results in poor prognosis. Due to the rarity of L-LCNEC, the efficacy and safety of immune checkpoint inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Zheng, Wei, Jingwen, Xu, Manyi, Song, Zhengbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482626/
https://www.ncbi.nlm.nih.gov/pubmed/37691658
http://dx.doi.org/10.21037/jtd-23-348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482626/
https://www.ncbi.nlm.nih.gov/pubmed/37691658
http://dx.doi.org/10.21037/jtd-23-348

Ejemplares similares